SEC Filings

Filing links are provided when reliable SEC filing data is available.

Recent Filings

Form	Filing Date	Accepted	Document
10-Q	Jul 30, 2026	Jul 30, 2026	View filing
8-K	Jul 30, 2026	Jul 30, 2026	View filing
4	Jun 3, 2026	Jun 3, 2026	View filing
4	Jun 3, 2026	Jun 3, 2026	View filing
3	Jun 3, 2026	Jun 3, 2026	View filing
144	Jun 1, 2026	Jun 1, 2026	View filing
8-K	May 27, 2026	May 27, 2026	View filing
4	May 22, 2026	May 22, 2026	View filing
4	May 22, 2026	May 22, 2026	View filing
4	May 22, 2026	May 22, 2026	View filing
4	May 22, 2026	May 22, 2026	View filing
4	May 22, 2026	May 22, 2026	View filing
4	May 22, 2026	May 22, 2026	View filing
4	May 22, 2026	May 22, 2026	View filing
4	May 22, 2026	May 22, 2026	View filing
4	May 22, 2026	May 22, 2026	View filing
4	May 14, 2026	May 14, 2026	View filing
SC 13G/A	May 14, 2026	May 14, 2026	View filing
SC 13G/A	May 14, 2026	May 14, 2026	View filing
SC 13G/A	May 6, 2026	May 6, 2026	View filing
10-Q	Apr 30, 2026	Apr 30, 2026	View filing
8-K	Apr 30, 2026	Apr 30, 2026	View filing
SC 13G	Apr 29, 2026	Apr 29, 2026	View filing
4	Apr 7, 2026	Apr 7, 2026	View filing
3	Apr 7, 2026	Apr 7, 2026	View filing
144	Apr 6, 2026	Apr 6, 2026	View filing
ARS	Apr 6, 2026	Apr 6, 2026	View filing
DEFA14A	Apr 6, 2026	Apr 6, 2026	View filing
DEF 14A	Apr 6, 2026	Apr 6, 2026	View filing
SC 13G/A	Mar 26, 2026	Mar 26, 2026	View filing

About Alnylam Pharmaceuticals, Inc.

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company primarily dedicated to the discovery, development, and commercialization of innovative therapeutic solutions leveraging ribonucleic acid interference (RNAi) technology. Its robust pipeline of RNAi-based treatments addresses a range of critical therapeutic areas, including inherited genetic disorders, cardio-metabolic conditions, hepatic infectious diseases, and central nervous system (CNS) and ocular disorders. Currently, Alnylam offers several approved therapies: ONPATTRO (patisiran) for adults suffering from polyneuropathy associated with hereditary transthyretin-mediated amyloidosis; GIVLAARI for adult patients with acute hepatic porphyria (AHP); and OXLUMO (lumasiran) for primary hyperoxaluria type 1 (PH1). Beyond its commercial portfolio, the company maintains an active development pipeline. Key investigational therapies include givosiran, aimed at adolescent patients with AHP; patisiran, being explored for transthyretin amyloidosis (ATTR) with cardiomyopathy; cemdisiran for complement-mediated disorders; ALN-AAT02 for AAT deficiency-associated liver disease; ALN-HBV02 for chronic hepatitis B virus infection; Zilebesiran for hypertension; and ALN-HSD for non-alcoholic steatohepatitis (NASH). Additionally, other candidates such as Fitusiran for hemophilia and bleeding disorders, Inclisiran for hypercholesterolemia, an expanded indication for lumasiran for advanced PH1 and recurrent kidney stones, and vutrisiran for ATTR amyloidosis (currently in Phase 3 clinical trials) are also progressing. Alnylam also engages in strategic alliances with other pharmaceutical leaders. Notable collaborations include those with Regeneron Pharmaceuticals, Inc., focused on discovering and developing RNAi therapeutics for ocular and CNS targets, and with Sanofi Genzyme for broader RNAi therapeutic development and commercialization efforts. Further licensing and partnership agreements are in place with entities such as Novartis AG, Vir Biotechnology, Inc., Dicerna Pharmaceuticals, Inc., Ionis Pharmaceuticals, Inc., and PeptiDream, Inc. Established in 2002, Alnylam Pharmaceuticals maintains its corporate headquarters in Cambridge, Massachusetts.

Cambridge, MA

2,500 employees

www.alnylam.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Yvonne L. Greenstreet

View full financials